Cargando…

A review of the use of inhaled nitric oxide in the PICU at Red Cross War Memorial Children’s Hospital, 2011-2015: A retrospective cohort study

BACKGROUND: Inhaled nitric oxide (iNO) functions as a selective pulmonary vasodilator. It is an expensive treatment that is often employed as rescue therapy for refractory hypoxaemia in acute respiratory distress syndrome (ARDS) and pulmonary hypertension (PHT) following cardiac surgery. OBJECTIVES:...

Descripción completa

Detalles Bibliográficos
Autores principales: Padayachee, S, Salie, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: South African Medical Association 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045499/
https://www.ncbi.nlm.nih.gov/pubmed/35493980
http://dx.doi.org/10.7196/SAJCC.2021.v37i2.416
_version_ 1784695330721234944
author Padayachee, S
Salie, S
author_facet Padayachee, S
Salie, S
author_sort Padayachee, S
collection PubMed
description BACKGROUND: Inhaled nitric oxide (iNO) functions as a selective pulmonary vasodilator. It is an expensive treatment that is often employed as rescue therapy for refractory hypoxaemia in acute respiratory distress syndrome (ARDS) and pulmonary hypertension (PHT) following cardiac surgery. OBJECTIVES: To describe the use of iNO and the cost of treatment in our paediatric intensive care unit (PICU). METHODS: A retrospective descriptive study of all patients treated with iNO in the PICU at Red Cross War Memorial Children’s Hospital (RCWMCH) from 2011 - 2015. RESULTS: We treated 140 patients with iNO, 82 for PHT following cardiac surgery, 53 for ARDS and 5 for persistent pulmonary hypertension of the newborn (PPHN). A response to treatment was observed in 64% of the cohort as a whole, 80% of those with PPHN, 67% of those with PHT post-cardiac surgery, and 64% of those with ARDS. A longer duration of PICU and hospital admission, and higher in-hospital mortality (53%), was seen in the group with ARDS, in particular those with adenoviral infection (63%), when compared with patients treated for PHT post-cardiac surgery (18%) and for PPHN (20%). The total cost of treatment with iNO was ZAR1 441 376 for the 5-year period studied. There are no protocols guiding the use of iNO in our unit, and it was found that response to treatment was not being objectively measured and documented, and that practice varied between clinicians. CONCLUSION: Considering the cost of treatment and lack of evidence showing improved outcomes with iNO therapy, its continued use in our resource-limited setting should be guided by protocol. CONTRIBUTIONS OF THE STUDY: There is a paucity of data regarding the indications for use, and outcomes of patients treated with iNO in resource-limited settings. We did not find evidence of improved outcomes in patients treated with iNO despite the high costs of the therapy. Protocols should be developed to guide the use of iNO in resource-limited settings.
format Online
Article
Text
id pubmed-9045499
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher South African Medical Association
record_format MEDLINE/PubMed
spelling pubmed-90454992022-04-28 A review of the use of inhaled nitric oxide in the PICU at Red Cross War Memorial Children’s Hospital, 2011-2015: A retrospective cohort study Padayachee, S Salie, S South Afr J Crit Care Research BACKGROUND: Inhaled nitric oxide (iNO) functions as a selective pulmonary vasodilator. It is an expensive treatment that is often employed as rescue therapy for refractory hypoxaemia in acute respiratory distress syndrome (ARDS) and pulmonary hypertension (PHT) following cardiac surgery. OBJECTIVES: To describe the use of iNO and the cost of treatment in our paediatric intensive care unit (PICU). METHODS: A retrospective descriptive study of all patients treated with iNO in the PICU at Red Cross War Memorial Children’s Hospital (RCWMCH) from 2011 - 2015. RESULTS: We treated 140 patients with iNO, 82 for PHT following cardiac surgery, 53 for ARDS and 5 for persistent pulmonary hypertension of the newborn (PPHN). A response to treatment was observed in 64% of the cohort as a whole, 80% of those with PPHN, 67% of those with PHT post-cardiac surgery, and 64% of those with ARDS. A longer duration of PICU and hospital admission, and higher in-hospital mortality (53%), was seen in the group with ARDS, in particular those with adenoviral infection (63%), when compared with patients treated for PHT post-cardiac surgery (18%) and for PPHN (20%). The total cost of treatment with iNO was ZAR1 441 376 for the 5-year period studied. There are no protocols guiding the use of iNO in our unit, and it was found that response to treatment was not being objectively measured and documented, and that practice varied between clinicians. CONCLUSION: Considering the cost of treatment and lack of evidence showing improved outcomes with iNO therapy, its continued use in our resource-limited setting should be guided by protocol. CONTRIBUTIONS OF THE STUDY: There is a paucity of data regarding the indications for use, and outcomes of patients treated with iNO in resource-limited settings. We did not find evidence of improved outcomes in patients treated with iNO despite the high costs of the therapy. Protocols should be developed to guide the use of iNO in resource-limited settings. South African Medical Association 2021-08-06 /pmc/articles/PMC9045499/ /pubmed/35493980 http://dx.doi.org/10.7196/SAJCC.2021.v37i2.416 Text en https://creativecommons.org/licenses/by-nc/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution - NonCommercial Works License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Padayachee, S
Salie, S
A review of the use of inhaled nitric oxide in the PICU at Red Cross War Memorial Children’s Hospital, 2011-2015: A retrospective cohort study
title A review of the use of inhaled nitric oxide in the PICU at Red Cross War Memorial Children’s Hospital, 2011-2015: A retrospective cohort study
title_full A review of the use of inhaled nitric oxide in the PICU at Red Cross War Memorial Children’s Hospital, 2011-2015: A retrospective cohort study
title_fullStr A review of the use of inhaled nitric oxide in the PICU at Red Cross War Memorial Children’s Hospital, 2011-2015: A retrospective cohort study
title_full_unstemmed A review of the use of inhaled nitric oxide in the PICU at Red Cross War Memorial Children’s Hospital, 2011-2015: A retrospective cohort study
title_short A review of the use of inhaled nitric oxide in the PICU at Red Cross War Memorial Children’s Hospital, 2011-2015: A retrospective cohort study
title_sort review of the use of inhaled nitric oxide in the picu at red cross war memorial children’s hospital, 2011-2015: a retrospective cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045499/
https://www.ncbi.nlm.nih.gov/pubmed/35493980
http://dx.doi.org/10.7196/SAJCC.2021.v37i2.416
work_keys_str_mv AT padayachees areviewoftheuseofinhalednitricoxideinthepicuatredcrosswarmemorialchildrenshospital20112015aretrospectivecohortstudy
AT salies areviewoftheuseofinhalednitricoxideinthepicuatredcrosswarmemorialchildrenshospital20112015aretrospectivecohortstudy
AT padayachees reviewoftheuseofinhalednitricoxideinthepicuatredcrosswarmemorialchildrenshospital20112015aretrospectivecohortstudy
AT salies reviewoftheuseofinhalednitricoxideinthepicuatredcrosswarmemorialchildrenshospital20112015aretrospectivecohortstudy